source
- An administrative gap delays access to new pancreatic cancer treatmentA new wave of illegal fruity vapes, more and more kids on GLP-1s, and other health news from Morning RoundsSTAT · 56m ago↗ source
- Inhibrx targets OX40 agonist-cancer vaccine studies from early next yearInhibrx Biosciences says its latest mid-stage results show the potential of its OX40 agonist in immunogenic cancers — but also its prospects in combination with cancer vaccines in tumors with lower…Endpoints · 58m ago↗ source
- STAT+: Inhibrx claims first win for long-sought immunotherapy target“Pushing this is like a rock up a hill, because there’s been so much failure in the space,” said Inhibrx CEO Mark Lappe.STAT · 58m ago